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Background: Multifocal glioblastoma is an uncommon and refractory subtype of high-grade glioma since the burden
of masses could not be eliminated simply by operation, and it is getting even harder to control if some deep structures,
like thalamus and pineal region, are involved.
Case presentation: Here we report a case of a 30-year-old male with multifocal glioblastoma affected his right
thalamus, left lateral ventricle, and pineal region. Clinical manifestations include operation, concurrent radiochemotherapy,
and a 12-cycle adjuvant temozolomide administration. The masses of this patient nearly disappeared after 15 months
from the primary diagnosis, and no severe adverse event or neurological sequel occurred.
Conclusions: Long-term temozolomide might be an optimal choice for patients with multifocal glioblastoma,
especially with deep-seated structure involvement.
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Glioblastoma multiforme (GBM) is the most common pri-
mary brain malignancy, and the median survival is less
than 15 months [1]. Multifocal glioblastoma has been de-
fined as glioblastoma being found synchronously in mul-
tiple foci, and there is a presumed microscopic connection
[2]. Multifocal glioblastoma often has a worse prognosis
than solitary ones. Several studies showed significantly
lower median survival about 7.6 to 12 months of patients
with newly diagnosed multifocal or multicentric glioblast-
oma compared to solitary ones [3-5], in spite of operation
plus radio-chemotherapy being carried out.
While radiotherapy with concomitant and adjuvant
temozolomide (6 cycles, 150 to 200 mg/m2/day) is the
standard treatment after surgery in glioblastoma pa-
tients, several institutions have studied on prolonged
administration of temozolomide and show increased* Correspondence: gaozx@ccmu.edu.cn
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unless otherwise stated.survival periods of these patients [6-9]. However, if the
lesions affect deep-seated structures, like thalamus or
post-third-ventricle structures, the operation is getting
harder and patients often have even worse outcomes.
Here we present a case report of a patient’s well-being
with multifocal glioblastoma of which the thalamus and
pineal regions were involved, who had received pro-
longed temozolomide in addition to standard treatment
and finally got a relatively optimistic prognosis. We
reviewed related literatures, considering that long-term
chemotherapy might be an option for treating patients
with deep-seated multifocal glioblastoma.Case presentation
First visit and examination
A 30-year-old man with no significant past medical history
or family history had felt numb of his left extremities
for 1 month. He also complained of mild headache and
interrupted vomiting. Physical examination at admission
revealed no abnormal signs such as asymmetric pupils or
hemiparesis. Cranial magnetic resonance imaging (MRI)s is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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was an occupying lesion at his right thalamus, with a
compressive deformation of the right ventricle. This
mass was mostly hyperintense on T1-weighted (T1W)
and T2-weighted (T2W) images. After gadolinium (Gd)
administration, the whole mass presented a heteroge-
neously enhanced character. While at the frontal angle
of the left ventricle as well as pineal body region, two
nodules with isointensity on both T1W and T2W im-
ages were detected, and they also mildly enhanced after
Gd administration (Figure 1A).
Initial resection
The patient underwent a right occipitotemporal cra-
niotomy after admission. With ultrasound guidance, a
4-cm-deep colostomy was carried out through the
patient’s supramarginal gyrus to the occipital angle of
the right ventricle. The mass was seen at the lateralFigure 1 The axial and sagittal contrast magnetic resonance
imaging (MRI) results of the patient. At primary diagnosis, there
were enhancements of the right thalamus, anterior angle of left
ventricle and pineal region (A, B). After the operation, the lesion of
the right thalamus was completely removed (C, D). Lesions on the
left ventricle and pineal region were eliminated after 12-cycle
administration of temozolomide (E, F).wall of the ventricle, with grey and red appearance,
uneven texture, and rich blood supply. There was an
obscure boundary between the mass and normal tissue
aside, as the tumor showed an infiltrative pattern of
growth. Resection within the mass had alleviated the
pressure, thus releasing some cerebrospinal fluid, which
lowered the pressure even more. Then a total resection
of the mass around its approximate boundary was
achieved (Figure 1B).
Histopathological examination
The examination was approved by the Institutional Re-
view Board of Beijing Tiantan Hospital, Capital Medical
University. On gross examination, the surgically excised
tissue, with a volume of 5.0 × 5.0 × 4.0 cm3 approxi-
mately, was heterogeneously soft and rough with pink-
ish color. On microscopic examination, the tumor was
composed of a mount of large and bizarre giant cells
with abundant eosinophilic cytoplasm on hematoxylin-
eosin (H-E) staining, which was compatible with a
diagnosis of glioblastoma. Scattered cells with loosely
cohesive cytoplasm (that is, ‘vacuole sign’) could be
seen, which indicated the presence of an oligodendro-
glioma component (Figure 2A). Immunohistochemi-
cally, the astrocytic tumor cells showed weakly positive
on the methylation of genes of O-6-methylguanine
DNA methyltransferase (MGMT) promoter (Figure 2B)
and strong mutation of phosphatase and tensin homo-
log (PTEN) genes (Figure 2C). Additionally, the tumor
cells were both immunoreactive for P53 (Figure 2D)
and had amplificated vascular endothelial growth factor
(VEGF) genes (Figure 2E). The immunofluorescent
staining of 1p19q showed there were no mutations
existed (Figure 2F).
Postoperative concurrent radiochemotherapy
After the resection, the patient presented with lucid
mind but mental fatigue, his left extremities’ muscle
strength is grade I, while his right ones’ is grade V. The
patient left the neurosurgery department with a wheel-
chair, and his Karnofsky Performance Scale (KPS) score
is 50. Concurrent radiotherapy and chemotherapy were
administered 1 week later, and the radiotherapy was
three-dimension conformal and intensity-modulated
which covered both the left ventricle and the surgical
cavity of the right thalamus, with a dosage of 58.0 Gy
in 29 fractions. At the meantime, the patient had con-
tinuous temozolomide, 160 mg (75 mg/m2/day) per day
for 42 days. During this adjuvant therapy, the patient’s
mental status got normalized, and his left hemiparesis
was gradually improved with grade-IV strength of the
arm and grade-III strength of the leg at the end of the
medication. Complications other than mild nausea did
not occur.
Figure 2 Histopathology of the tumor of the patient. A mount of large and bizarre giant cells compatible with a diagnosis of glioblastoma in
the H-E staining (A). Immunohistochemically, the MGMT promoter was weakly methylated (B) and strong mutation of PTEN genes (C), P53 (D),
and amplificated VEGF genes (E) were seen. The immunofluorescent staining of 1p19q showed no deficiency existed (F).
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A follow-up MRI study performed 4 weeks after radio-
therapy (14 weeks after resection) showed thickened
enhancement after Gd administration in the pineal body
region and the frontal angle of the left ventricle, com-
pared with the pre-radiation MRI study, which might in-
dicate tumor dissemination to these areas. Adjuvant
temozolomide with 150 to 200 mg/m2 for 5 days every
28 days was then administered to the patient for 12 cy-
cles. During the long-term therapy, the patient was
followed by MRI and clinical visits every 2 to 4 months.
Blood testing for hematologic toxicity was performed
every cycle, and the results did not show abnormal
blood cell counting or changes in liver and kidney func-
tions. Gastrointestinal toxicity or allergy was also not
seen. After 8 cycles, the MRI showed significantly weak-
ened signal in the frontal angle of left ventricle as well as
the pineal body region on the Gd enhanced images. At
the end of the 12-cycle therapy, the enhancement area
of left ventricle almost disappeared, the same change
presented in the pineal body region as well (Figure 1C).
At the recent clinical visit, the patient showed normal
mental status, along with grade-IV muscle strength of
his left extremities. The patient was back to work as a
green worker, and his KPS score was improved to 90.
Discussion
Multifocal glioblastoma is defined as intracranial GBM
with multiple synchronous foci, and there is a known
anatomical route for spread of diseases between lesions.
It only consists of a small part of glioblastoma, with an
incidence of 0.5% to 20% [7,10,11]. Thomas et al. re-
ported that with the help of improved imaging technol-
ogy, the incidence of multiple GBM would increase [12],
but deep-seated multifocal GBM, with thalamus andpost-third-ventricle structure involved, remains rare and
few literatures have been published to explain this dis-
ease. The presented case was a young male with multiple
lesions located at his right thalamus, the frontal angle
of the left ventricle and the pineal region were also
involved, which made this case even rarer since the
tumors of the pineal region only consisted of 0.5% to
2% of all intracranial neoplasms in several researches
[13-15]. The multiple lesions made the treatment very
complicated since one operation was not enough. We
chose the craniotomy of a right lateral ventricle ap-
proach to remove the thalamic lesion since it was the
largest one, which caused the neurological focal signs.
From the postoperative MRI, gross total resection was
achieved of this single target.
Multifocal GBM has many ways to spread intracranially,
such as through commissual pathways, cerebrospinal
channels, blood vessels, or by local dissemination through
satellite formation [12]. The patient’s GBM presented in
this literature probably had spread by a way combined
with transventricular and subependymal routes, which was
an uncommon pathway described by Kyritsis et al. [16].
Several literatures mentioned that GBM contained cells
propagated from astrocyte-like neural stem cells within
the subventricular zone (SVZ), which was located just
under the ependymal of the brain ventricles [17,18]. Lim
et al. [19] pointed out that GBMs with contact to SVZ
were most likely to be multifocal at diagnosis. We ad-
dressed that the thalamic mass, which caused the right
ventricle compression of this patient, might had different
cells of origin and, thus, was responsible for its me-
tastatic behavior. Pathological examinations for this
tumor revealed a PTEN-mutated, MGMT-methylated,
and VEGF-amplificated condition. Many pathological
researches revealed PTEN mutation was a common
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found nonsense mutation located in exon 7 in the cell
lines of three multifocal GBM, and this mutation was
identified in the original tumor tissue but not in the
germ-line DNA, which suggested that the mutation was
an early event of pathogenesis of the tumor before it
separated into different lesions. Recently, Xu et al. [24]
found that PTEN nonsense mutations increased gen-
omic instability of GBM and shortened disease-free
survival of GBM patients. On the other hand, some re-
searches caught thoughts of brain tumor stem cells had
higher expression of VEGF and, as a result, built a suit-
able niche for tumor proliferation [25,26]. For example,
Bao et al. found that bevacizumab, a well known anti-
angiogenic agent, suppressed growth of stem cell-like
glioma cells but limited efficacy against those derived
from non-stem cell-like glioma cells in vivo [27] and,
thus, might give an explanation to the different progno-
sis among patients under the treatment of bevacizu-
mab. Under these analyses, we could infer that the
tumor of the patient presented here might be generated
from stem cells located close to SVZ; with the help
of mutated PTEN genes and overexpression of VEGF,
the tumor acquired highly progressive and metastatic
features and showed characteristics of multifocal distri-
bution. On the other hand, although 1p19q deletion
is a well-known index for good prognosis, especially
the sensitivity to temozolomide [28], this patient with
1p19q not deleted did show a positive response to
chemotherapy.
The standard treatment for GBM includes surgery,
temozolimide concomitant with radiotherapy, and followed
by 6 cycles of adjuvant temozolomide. According to the re-
sults of EORTC trial EORTC-26981/CAN-NCIC- CE3, pa-
tients with GBM had a progression free survival (PFS) after
6 months of 53%, a median survival of 14.6 months, and a
2-year survival rate of 26.5% [1]. In fact, the best duration
of adjuvant chemotherapy for patients with GBM is un-
known. More and more clinicians started using temozolo-
mide beyond 6 cycles. For example, Balañá et al. [29]
mentioned that temozolomide treatment was continued
for more than 6 cycles by 80.5% of neuro-oncologists in
Spain. There are many kinds of long-term usage of temo-
zolomide nowadays, three distinctive regimens are stand-
ard ‘5/28’ protocol (150 to 200 mg/m2 on days 1 to 5 every
28 days) [6], ‘1 week on-1 week off ’ protocol (150 mg/m2
on days 1 to 7 and 15 to 21 of a 28-day cycle) [7], and
dose-dense protocol (75 to 100 mg/m2 on days 1 to 21
every 28 days) [30].
For the presented patient, we chose the ‘5/28’ protocol:
in addition to the standard 6 cycles, 6 more cycles of
temozolomide (200 mg/m2) was added until recent clin-
ical visit. After 8 cycles, significantly weakened signals in
the frontal angle of left ventricle along with the pinealregion on the Gd-enhance T1W image were seen, and
after a 12-cycle chemotherapy, the enhancement of these
two areas almost vanished. Epigenetic silencing by pro-
moter methylation causes decreased MGMT expression
and, thus, cannot maintain genomic integrity properly
[31,32]. Many clinical researches found correlation be-
tween prognosis of patients with GBM and MGMT pro-
moter methylation [32-34]. This patient had a methylated
MGMT, and the response to extended temozolomide
administration was well, which could prove that tailored
plans for different patients due to their subtle pathological
distinctions were necessary [35,36].
The patient tolerated this prolonged treatment well
since no hematological or gastrointestinal toxicity oc-
curred, and the tumor was controlled ideally. These results
were consistent with many other clinical researches. Hau
et al. [37] reported patients with primary GBM received a
median of 13 cycles of temozolomide and had a time to
progression (TTP) of 15 months and 2-year survival rates
of 68%, and adverse events were thrombocytopenia (10%),
leukopenia (7%), gastrointestinal toxicity (5%), and infec-
tion (4%). Seiz et al. [9] found that TTP and overall sur-
vival (OS) directly correlated with the amount of therapy,
since there was a significant improvement of OS of pa-
tients who received more than 6 cycles of temozolomide
compared to those who did not; by the way, moderate
thrombocytopenia and pancytopenia occurred in 10% of
all patients. Urgoiti et al. [8] reported a median survival of
24.6 months with minimal toxicity of patients who had
more than 6 cycles, rather than 16.5 months for those
stopped at cycle 6. Darlix et al. [6] also reported improve-
ment of OS and PFS for patients with GBM who received
at least 9 cycles (median = 14) of temozolomide than those
who received 6 cycles (3-year PFS: 43.5% vs. 11%, 3-year
OS: 48% vs. 22%).
There are still some limitations of our research. One is
that exact pathologic study of every lesion seen in the
MRI was not completely obtained. Since this patient has
rapidly progressed and significant clinical manifestation
was seen at the first view, we decided to resect the re-
sponsible lesion located in the right thalamus. And be-
cause the other lesions are diffusely located, one in the
pineal region and the other in the frontal angle of the
left lateral ventricle, we thought that multiple resections
or biopsies might lead to a worse prognosis and delay
the proper time of radiotherapy. Thus we did not have
all lesions on the MRI under pathologic scan.
And also there might be other factors that help the pa-
tient have a good prognosis. Firstly, the patient has been
under an operation which has released a lot of burden
on the tumor. Secondly, this is a young patient with
good tolerance to the possible side effects of long-term
usage of temozolomide. Thirdly, this patient’s health
insurance could cover the high expenses of 12-month
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support for the patient and his family. Other patients
with similar tumor characteristics of this one have been
reviewed. Further data is under analysis.
Conclusions
In summary, we propose that for patients with multi-
focal deep-seated glioblastoma multiforme, the resection
of dominant lesion is the first and most fundamental
step. Thorough pathologic examination for infiltrative
and proliferative markers is necessary. Long-term temo-
zolomide administration following the standard therapy
might be a good choice for this kind of refractory tumor.
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